Improving Multivitamin Supplementation to Pregnant Women

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare the tolerability of Pregvit® to a common prenatal vitamin (Orifer® F) among pregnant women with morning sickness or those suffering from a variety of conditions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Hospital for Sick Children
• Collaborator: Duchesnay Inc.

Criteria

Inclusion Criteria:

Any woman who discontinued her standard vitamins due to gastrointestinal symptoms or due to the tablet size, with one ofthe following conditions:

• Morning sickness.

• Gastrointestinal disorders: Crohn's disease, ulcerative colitis, peptic or duodenal ulcer, irritable colon, celiac disease.

• Iron deficiency anemia.

• Hypothyroidism.

• Depression.

Exclusion Criteria:

• Women who do not agree to consent to this protocol.

• Women with a known hypersensitivity to any of the ingredients of Pregvit®, or Orifer® F.